White & Case advises Sun Pharma on US$11.75 billion acquisition of Organon

Global law firm White & Case LLP has advised Sun Pharmaceutical Industries Limited (“Sun Pharma") (NSE: SUNPHARMA, BSE: 524715) on its entry into an agreement to acquire all outstanding shares of Organon & Co. (“Organon") (NYSE: OGN) for an enterprise valuation of US$11.75 billion.

Sun Pharma is the world's leading specialty generics company and is the largest pharmaceutical company in India. Organon is a global healthcare company with a portfolio of more than 70  products across women's health and general medicines.

The White & Case team was led by M&A partners Keith Hallam (New York) and Matthew Barnett (Los Angeles).

The team also included Technology Transactions partner Andres Liivak (Boston) and associate Sahra Nizipli (New York); Intellectual Property partner Anita Varma (Boston) and associate Hallie Kiernan (New York); Employment, Compensation & Benefits partner Sasha Belinkie and associates Jacob Smith (both in New York) and Lucee Laursen (Chicago); Debt Finance partners Justin Wagstaff (New York) and Alexander McMyn (Dubai), counsel Eriq Yu (New York) and associate Hussain Ali (Dubai); Capital Markets partner Gary Kashar and associate Joanna Heinz (both in New York); Antitrust partners Strati Sakellariou-Witt (Brussels) and Anna Kertesz (Washington, DC) and associates Tommaso Poli, Daphne Emvalomenos (both in Brussels), Allain Andry and Andrew Hamm (both in Washington, DC); Trade partner Orion Berg and associate Clémence  Flichy (both in Paris); Healthcare Regulatory partner Bethany Hills (New York); and M&A associates Joshua Butler, Parmeet Batra and Emilia Calderon (all in New York). Law clerks Andi Khalaf, Erica Smith and Holly Ryan (all in New York) also advised on the matter.

Press contact
For more information please speak to your local media contact.